Forefront Analytics, LLC Poseida Therapeutics, Inc. Transaction History

Forefront Analytics, LLC

  • $209 Million
  • Q2 2024

A detailed history of Forefront Analytics, LLC transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Forefront Analytics, LLC holds 29,817 shares of PSTX stock, worth $73,051. This represents 0.04% of its overall portfolio holdings.

Number of Shares
29,817
Previous 26,780 11.34%
Holding current value
$73,051
Previous $85,000 2.35%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$2.0 - $3.46 $6,074 - $10,508
3,037 Added 11.34%
29,817 $87,000
Q1 2024

May 15, 2024
BUY
$2.76 - $4.13 $3,618 - $5,414
1,311 Added 5.15%
26,780 $85,000
Q4 2023

Feb 13, 2024
BUY
$1.83 - $3.51 $915 - $1,755
500 Added 2.0%
25,469 $85,000
Q3 2023

Nov 07, 2023
SELL
$1.62 - $2.79 $2,673 - $4,603
-1,650 Reduced 6.2%
24,969 $59,000
Q2 2023

Aug 11, 2023
BUY
$1.66 - $3.4 $19,221 - $39,368
11,579 Added 76.99%
26,619 $46,000
Q1 2023

May 11, 2023
SELL
$3.08 - $8.73 $708 - $2,007
-230 Reduced 1.51%
15,040 $46,000
Q4 2022

Feb 13, 2023
SELL
$3.33 - $6.38 $1,265 - $2,424
-380 Reduced 2.43%
15,270 $80,000
Q3 2022

Nov 14, 2022
SELL
$2.43 - $4.51 $18,759 - $34,817
-7,720 Reduced 33.03%
15,650 $59,000
Q2 2022

Aug 10, 2022
SELL
$1.87 - $5.0 $6,358 - $17,000
-3,400 Reduced 12.7%
23,370 $61,000
Q1 2022

May 09, 2022
BUY
$3.22 - $7.04 $52,003 - $113,696
16,150 Added 152.07%
26,770 $121,000
Q4 2021

Feb 11, 2022
BUY
$6.23 - $7.6 $1,713 - $2,090
275 Added 2.66%
10,620 $72,000
Q3 2021

Nov 15, 2021
BUY
$7.09 - $10.71 $73,346 - $110,794
10,345 New
10,345 $72,000

Others Institutions Holding PSTX

# of Institutions
95
Shares Held
38.2M
Call Options Held
417K
Put Options Held
42.7K
View Full List

About Poseida Therapeutics, Inc.

PSTX Quotes by TradingView
  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $210M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Forefront Analytics, LLC Portfolio

Follow Forefront Analytics, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Forefront Analytics, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Forefront Analytics, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email